Targeting IGF2BP1 or IGF2BP1-modulated SEMA3A expression in NB cells and their resulting EVs prevented this PMN formation and metastasis in mice, suggesting the potential therapeutic application of targeting this axis for NB treatments. The gene discussed is IGF2BP1; the disease is neuroblastoma.